Market Overview

AstraZeneca Confirms Exploring Potential Strategic Options With Acerta Pharma

Related AZN
Pfizer Reports Updated Data From Phase III Study On Ibrance
FDA Decisions In November: The Month In Review
FDA accepts AstraZeneca's marketing application for Tagrisso in first-line EGFR+ NSCLC (Seeking Alpha)

Further to recent speculation, AstraZeneca (NYSE: AZN) confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.

The Company will make a further announcement if and when appropriate.

Dow Jones first reported a potential deal between the companies on Friday.

AstraZeneca shares closed down $0.22 on Friday, at $33.25.

Posted-In: News M&A Press Releases


Related Articles (AZN)

View Comments and Join the Discussion!